Company insiders in the life science and diagnostic tools sector disposed of roughly $187 million of stock during the first quarter of 2026, according to a Barclays analysis released Tuesday. The review spanned 20 companies and showed a pronounced imbalance between insider selling and buying in the period.
Only five companies in the sample recorded net insider purchases in the open market during the quarter. Those firms were Avantor Inc (NYSE:AVTR), Waters Corp (NYSE:WAT), Illumina Inc (NASDAQ:ILMN), Quest Diagnostics Inc (NYSE:DGX), and Charles River Laboratories International Inc (NYSE:CRL).
Avantor stood out as the largest open-market buyer in absolute terms, with insiders purchasing about $2.4 million of stock in the quarter. That buying represented approximately 0.04% of the company’s shares outstanding and marked the fourth consecutive quarter in which insiders bought shares at Avantor. Barclays noted that insiders have purchased about $11.2 million of Avantor stock since the second quarter of 2025.
The other four buying companies registered much smaller open-market purchases. Insider acquisitions at Waters, Illumina, Quest Diagnostics, and Charles River were each below 0.01% of their respective shares outstanding, indicating limited scale compared with typical market volumes.
On the selling side, Medpace Holdings Inc (NASDAQ:MEDP) recorded the largest open-market insider sales in the quarter, with roughly $14 million of stock sold - approximately 32,000 shares, or about 0.11% of shares outstanding. Guardant Health Inc (NASDAQ:GH) followed with about $6 million in open-market sales, representing roughly 63,000 shares.
Twist Bioscience Corp (NASDAQ:TWST) insiders sold about $5 million of stock in the open market, equating to roughly 100,000 shares or about 0.17% of shares outstanding.
A notable feature of the selling activity was the scale of pre-scheduled transactions at Natera Inc (NASDAQ:NTRA). Insiders at Natera executed roughly $123 million of sales in the period - about 568,000 shares - and Barclays reported that nearly all of those trades were pre-scheduled.
When aggregated, open-market insider purchases in the sector totaled approximately $2.9 million for the first quarter, while total open-market sales amounted to about $33 million. The broader figure of $187 million in insider sales cited by Barclays reflects both open-market and pre-scheduled dispositions across the 20-company sample.
Key points
- Insiders across 20 life science and diagnostic companies sold an estimated $187 million of stock during Q1 2026.
- Net open-market insider buying was concentrated in five firms, led by Avantor, while open-market purchases totaled about $2.9 million versus $33 million in open-market sales.
- One company, Natera, accounted for the largest portion of seller proceeds through nearly all pre-scheduled sales, totaling roughly $123 million.
Risks and uncertainties
- Concentration of sales in pre-scheduled transactions at a single company creates uncertainty about the timing and drivers of supply into the market - affecting the diagnostics and life sciences sector.
- The small scale of open-market insider purchases relative to sales suggests limited insider buying support in the sector, which could influence investor sentiment in life sciences and diagnostics stocks.
- Material open-market sales by several companies introduce potential near-term share supply that market participants in biotech, diagnostics, and related equities will need to absorb.
The Barclays analysis provides a snapshot of insider behavior across the selected cohort of life science and diagnostic tools companies for the first quarter. It highlights that while a handful of companies saw insider purchasing, selling activity - including substantial pre-scheduled dispositions at one firm - dominated the period.